At momoby, we believe every woman should have access to prenatal care, regardless of where she lives. To tackle this challenge, we’re developing a low cost, pocket-sized device that tests for diseases that could harm pregnancy, using a single drop of blood.
By Rachel Dunscombe, CEO, NHS Digital Academy
Standing in the Royal Society on the 16th of April waiting for the participants to arrive was both surreal and exciting. Surreal because of the rapid journey our wonderful team had taken to make the programme happen – this had become a reality so quickly. Exciting because I couldn’t wait to get started – this programme is important for the system and for me something I am hugely committed to.
The Digital Academy operational team, of which I am a part, are all keen to ensure that this programme is as grounded in digital leaders’ practice as much as possible rather than being too high end academic.
By IGHI guest blogger, Chris Bird, PG student from the MSC in Health Policy at the Centre for Health Policy and Project Manager in the System Engagement Programme at the National Institute for Health and Care Excellence (NICE)
At a recent conference I was lucky to listen to a guest lecture by Dr Kevin Fong. Kevin has a long standing interest in human space exploration and space medicine and has worked with NASA’s Human Adaptation and Countermeasures Office at the Johnson Space Centre in Houston. He’s travelled the world to meet medical innovators and has produced interesting documentaries for television showing the extreme scenarios in which healthcare and technology can be applied to further human survival.
By Student Challenges Competition 2015/16 Audience Choice Award winners, Antonios Chronopoulos and Tyler Lieberthal
Pancreatic cancer has the lowest survival rate of all major cancers and is widely regarded as a death sentence. The 5-year survival rate is still in the single digits at 3% and this figure has not changed over the past four decades largely due to lack of specific therapies and inability of early detection. Symptoms rarely develop with early disease, which translates to more than 85% of patients receiving their diagnosis at an advanced stage when the tumour is metastatic and no longer treatable. Modern imaging techniques, such as CT and MRI are expensive and unable to detect early-stage lesions.
By guest blogger and Imperial alumnus Margaux Lesaffre
Stroke is the silent killer; there are no clear symptoms until people realise they can’t talk, move or even swallow. Annually, over 5 million deaths worldwide are caused by strokes, ranking this disease in the first ten leading cause of deaths. In developed countries, the incidence of stroke is dropping, but the outcome is still severe with some stroke victims left permanently disabled.
So what’s the way forward?
University researchers have developed remarkable innovations that could deliver significantly more reliable diagnostics and treatment. This blog looks at different ways university research can tackle this insidious disease.